LC–MS-based quantitation of proteomic changes induced by Norcantharidin in MTB-Treated macrophages
Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation of macrophage-mediated anti-tuberculosis immunity being crucial. Norcantharidin (NCTD), a drug used in tumor immunotherapy, has significant im...
Saved in:
| Published in | Proteome science Vol. 22; no. 1; pp. 13 - 10 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
04.12.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation of macrophage-mediated anti-tuberculosis immunity being crucial. Norcantharidin (NCTD), a drug used in tumor immunotherapy, has significant immunomodulatory effects. Thus, NCTD may have an anti-tuberculosis role by regulating immunity. Understanding how NCTD affects the proteome of Mtb-infected macrophages can provide valuable insights into potential treatments. This study aimed to investigate the impact of NCTD (10 μg/mL) on the proteome of macrophages infected with Mtb H37Ra using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. A total of 69 differentially regulated proteins (DRPs) were identified, with 28 up-regulated and 41 down-regulated in the NCTD-treated group. Validation of six DRPs (CLTCL1, VAV1, SP1, TRIM24, MYO1G, and WDR70) by Western blot analysis confirmed the accuracy of the LC-MS/MS method used in this study. NCTD modulates various protein expressions involved in chromatin-modifying enzymes, RHO GTPases activating PAKs, Fc gamma R-mediated phagocytosis, T cell receptor signaling pathway, and antigen processing and presentation. Overall, the research provides new insights into the effects of NCTD on the proteome of Mtb-infected macrophages. The identified changes highlight potential targets for future therapeutic interventions aimed at enhancing host immunity against Mtb infection or developing new anti-TB drugs based on these findings. |
|---|---|
| AbstractList | Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation of macrophage-mediated anti-tuberculosis immunity being crucial. Norcantharidin (NCTD), a drug used in tumor immunotherapy, has significant immunomodulatory effects. Thus, NCTD may have an anti-tuberculosis role by regulating immunity. Understanding how NCTD affects the proteome of Mtb-infected macrophages can provide valuable insights into potential treatments. This study aimed to investigate the impact of NCTD (10 μg/mL) on the proteome of macrophages infected with Mtb H37Ra using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. A total of 69 differentially regulated proteins (DRPs) were identified, with 28 up-regulated and 41 down-regulated in the NCTD-treated group. Validation of six DRPs (CLTCL1, VAV1, SP1, TRIM24, MYO1G, and WDR70) by Western blot analysis confirmed the accuracy of the LC-MS/MS method used in this study. NCTD modulates various protein expressions involved in chromatin-modifying enzymes, RHO GTPases activating PAKs, Fc gamma R-mediated phagocytosis, T cell receptor signaling pathway, and antigen processing and presentation. Overall, the research provides new insights into the effects of NCTD on the proteome of Mtb-infected macrophages. The identified changes highlight potential targets for future therapeutic interventions aimed at enhancing host immunity against Mtb infection or developing new anti-TB drugs based on these findings.Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation of macrophage-mediated anti-tuberculosis immunity being crucial. Norcantharidin (NCTD), a drug used in tumor immunotherapy, has significant immunomodulatory effects. Thus, NCTD may have an anti-tuberculosis role by regulating immunity. Understanding how NCTD affects the proteome of Mtb-infected macrophages can provide valuable insights into potential treatments. This study aimed to investigate the impact of NCTD (10 μg/mL) on the proteome of macrophages infected with Mtb H37Ra using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. A total of 69 differentially regulated proteins (DRPs) were identified, with 28 up-regulated and 41 down-regulated in the NCTD-treated group. Validation of six DRPs (CLTCL1, VAV1, SP1, TRIM24, MYO1G, and WDR70) by Western blot analysis confirmed the accuracy of the LC-MS/MS method used in this study. NCTD modulates various protein expressions involved in chromatin-modifying enzymes, RHO GTPases activating PAKs, Fc gamma R-mediated phagocytosis, T cell receptor signaling pathway, and antigen processing and presentation. Overall, the research provides new insights into the effects of NCTD on the proteome of Mtb-infected macrophages. The identified changes highlight potential targets for future therapeutic interventions aimed at enhancing host immunity against Mtb infection or developing new anti-TB drugs based on these findings. Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation of macrophage-mediated anti-tuberculosis immunity being crucial. Norcantharidin (NCTD), a drug used in tumor immunotherapy, has significant immunomodulatory effects. Thus, NCTD may have an anti-tuberculosis role by regulating immunity. Understanding how NCTD affects the proteome of Mtb -infected macrophages can provide valuable insights into potential treatments. This study aimed to investigate the impact of NCTD (10 μg/mL) on the proteome of macrophages infected with Mtb H37Ra using liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis. A total of 69 differentially regulated proteins (DRPs) were identified, with 28 up-regulated and 41 down-regulated in the NCTD-treated group. Validation of six DRPs (CLTCL1, VAV1, SP1, TRIM24, MYO1G, and WDR70) by Western blot analysis confirmed the accuracy of the LC–MS/MS method used in this study. NCTD modulates various protein expressions involved in chromatin-modifying enzymes, RHO GTPases activating PAKs, Fc gamma R-mediated phagocytosis, T cell receptor signaling pathway, and antigen processing and presentation. Overall, the research provides new insights into the effects of NCTD on the proteome of Mtb -infected macrophages. The identified changes highlight potential targets for future therapeutic interventions aimed at enhancing host immunity against Mtb infection or developing new anti-TB drugs based on these findings. Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation of macrophage-mediated anti-tuberculosis immunity being crucial. Norcantharidin (NCTD), a drug used in tumor immunotherapy, has significant immunomodulatory effects. Thus, NCTD may have an anti-tuberculosis role by regulating immunity. Understanding how NCTD affects the proteome of Mtb-infected macrophages can provide valuable insights into potential treatments. This study aimed to investigate the impact of NCTD (10 μg/mL) on the proteome of macrophages infected with Mtb H37Ra using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. A total of 69 differentially regulated proteins (DRPs) were identified, with 28 up-regulated and 41 down-regulated in the NCTD-treated group. Validation of six DRPs (CLTCL1, VAV1, SP1, TRIM24, MYO1G, and WDR70) by Western blot analysis confirmed the accuracy of the LC-MS/MS method used in this study. NCTD modulates various protein expressions involved in chromatin-modifying enzymes, RHO GTPases activating PAKs, Fc gamma R-mediated phagocytosis, T cell receptor signaling pathway, and antigen processing and presentation. Overall, the research provides new insights into the effects of NCTD on the proteome of Mtb-infected macrophages. The identified changes highlight potential targets for future therapeutic interventions aimed at enhancing host immunity against Mtb infection or developing new anti-TB drugs based on these findings. Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation of macrophage-mediated anti-tuberculosis immunity being crucial. Norcantharidin (NCTD), a drug used in tumor immunotherapy, has significant immunomodulatory effects. Thus, NCTD may have an anti-tuberculosis role by regulating immunity. Understanding how NCTD affects the proteome of Mtb-infected macrophages can provide valuable insights into potential treatments. This study aimed to investigate the impact of NCTD (10 [mu]g/mL) on the proteome of macrophages infected with Mtb H37Ra using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. A total of 69 differentially regulated proteins (DRPs) were identified, with 28 up-regulated and 41 down-regulated in the NCTD-treated group. Validation of six DRPs (CLTCL1, VAV1, SP1, TRIM24, MYO1G, and WDR70) by Western blot analysis confirmed the accuracy of the LC-MS/MS method used in this study. NCTD modulates various protein expressions involved in chromatin-modifying enzymes, RHO GTPases activating PAKs, Fc gamma R-mediated phagocytosis, T cell receptor signaling pathway, and antigen processing and presentation. Overall, the research provides new insights into the effects of NCTD on the proteome of Mtb-infected macrophages. The identified changes highlight potential targets for future therapeutic interventions aimed at enhancing host immunity against Mtb infection or developing new anti-TB drugs based on these findings. Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation of macrophage-mediated anti-tuberculosis immunity being crucial. Norcantharidin (NCTD), a drug used in tumor immunotherapy, has significant immunomodulatory effects. Thus, NCTD may have an anti-tuberculosis role by regulating immunity. Understanding how NCTD affects the proteome of Mtb-infected macrophages can provide valuable insights into potential treatments. This study aimed to investigate the impact of NCTD (10 [mu]g/mL) on the proteome of macrophages infected with Mtb H37Ra using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. A total of 69 differentially regulated proteins (DRPs) were identified, with 28 up-regulated and 41 down-regulated in the NCTD-treated group. Validation of six DRPs (CLTCL1, VAV1, SP1, TRIM24, MYO1G, and WDR70) by Western blot analysis confirmed the accuracy of the LC-MS/MS method used in this study. NCTD modulates various protein expressions involved in chromatin-modifying enzymes, RHO GTPases activating PAKs, Fc gamma R-mediated phagocytosis, T cell receptor signaling pathway, and antigen processing and presentation. Overall, the research provides new insights into the effects of NCTD on the proteome of Mtb-infected macrophages. The identified changes highlight potential targets for future therapeutic interventions aimed at enhancing host immunity against Mtb infection or developing new anti-TB drugs based on these findings. Keywords: Norcantharidin, Mycobacterium tuberculosis, H37Ra, Macrophage, Proteome Abstract Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation of macrophage-mediated anti-tuberculosis immunity being crucial. Norcantharidin (NCTD), a drug used in tumor immunotherapy, has significant immunomodulatory effects. Thus, NCTD may have an anti-tuberculosis role by regulating immunity. Understanding how NCTD affects the proteome of Mtb-infected macrophages can provide valuable insights into potential treatments. This study aimed to investigate the impact of NCTD (10 μg/mL) on the proteome of macrophages infected with Mtb H37Ra using liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis. A total of 69 differentially regulated proteins (DRPs) were identified, with 28 up-regulated and 41 down-regulated in the NCTD-treated group. Validation of six DRPs (CLTCL1, VAV1, SP1, TRIM24, MYO1G, and WDR70) by Western blot analysis confirmed the accuracy of the LC–MS/MS method used in this study. NCTD modulates various protein expressions involved in chromatin-modifying enzymes, RHO GTPases activating PAKs, Fc gamma R-mediated phagocytosis, T cell receptor signaling pathway, and antigen processing and presentation. Overall, the research provides new insights into the effects of NCTD on the proteome of Mtb-infected macrophages. The identified changes highlight potential targets for future therapeutic interventions aimed at enhancing host immunity against Mtb infection or developing new anti-TB drugs based on these findings. |
| ArticleNumber | 13 |
| Audience | Academic |
| Author | Liang, Jin Liu, Gan-Bin Li, Yuan-Ting Huang, Qi-Dan Gao, Xin-Xuan Ouyang, Jia-Yi Wu, Jun-Yi Zhang, Jun-Ai Wu, Jin-Lin Cai, Xiao-Zhen Gao, Yu-Chi Wu, Yi-Lin Ding, Yi-Ran Lu, Yuan-Bin Liu, Xiao-Ran |
| Author_xml | – sequence: 1 givenname: Yi-Lin surname: Wu fullname: Wu, Yi-Lin – sequence: 2 givenname: Yuan-Ting surname: Li fullname: Li, Yuan-Ting – sequence: 3 givenname: Gan-Bin surname: Liu fullname: Liu, Gan-Bin – sequence: 4 givenname: Jin-Lin surname: Wu fullname: Wu, Jin-Lin – sequence: 5 givenname: Xiao-Ran surname: Liu fullname: Liu, Xiao-Ran – sequence: 6 givenname: Xin-Xuan surname: Gao fullname: Gao, Xin-Xuan – sequence: 7 givenname: Qi-Dan surname: Huang fullname: Huang, Qi-Dan – sequence: 8 givenname: Jin surname: Liang fullname: Liang, Jin – sequence: 9 givenname: Jia-Yi surname: Ouyang fullname: Ouyang, Jia-Yi – sequence: 10 givenname: Yi-Ran surname: Ding fullname: Ding, Yi-Ran – sequence: 11 givenname: Jun-Yi surname: Wu fullname: Wu, Jun-Yi – sequence: 12 givenname: Yuan-Bin surname: Lu fullname: Lu, Yuan-Bin – sequence: 13 givenname: Yu-Chi surname: Gao fullname: Gao, Yu-Chi – sequence: 14 givenname: Xiao-Zhen surname: Cai fullname: Cai, Xiao-Zhen – sequence: 15 givenname: Jun-Ai surname: Zhang fullname: Zhang, Jun-Ai |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39633431$$D View this record in MEDLINE/PubMed |
| BookMark | eNptks1uEzEQx1eoiH7AC3BAK3Ghhy2etde7PqE24iNSChINZ8tfm7hK7NTeReTWd-ANeRKmTakaCfkw1sxv_vZo_sfFQYjBFcVrIGcAHX-foRYNrUjNKkJq2lTbZ8URsLatGtHwgyf3w-I452uEalHzF8UhFZxSRuGosLPJn9vfl1eVVtnZ8mZUYfCDGnwMZezLTYqDi2tvSrNUYeFy6YMdDZJ6W36NySC-VMlbH7BSXs4vqnlyakBgrUyKm6XCppfF816tsnv1EE-KH58-zidfqtm3z9PJ-awyTQ1DZXsqKCMauKmFA6Z1w2ytrOWGMdYyYqxyhLe8dQRjI7Trweq-JZQ0AJqeFNOdro3qWm6SX6u0lVF5eZ-IaSFVGrxZOWkY1z1pXUMNMMG6DngtSK_BcEbxedT6sNPajHrtrHFhSGq1J7pfCX4pF_GnBOAggHSo8O5BIcWb0eVBrn02brVSwcUxSwqM49ysqxF9u0MXCv_mQx9R0tzh8ryDTghGW0Dq7D8UHutwQ-iN3mN-r-F0rwGZwf0aFmrMWU6vvu-zb57O-zjoP6sgUO8AXGvOyfWPCBB550e586NEP8p7P8ot_Qu5ltG9 |
| Cites_doi | 10.1080/14760584.2019.1704263 10.1186/s13018-024-04678-z 10.3389/fcimb.2016.00147 10.1038/s41467-022-28506-2 10.1080/15548627.2018.1483806 10.1128/mbio.00272-23 10.3390/microorganisms11071846 10.1016/j.febslet.2009.11.096 10.1038/s41598-021-85477-y 10.4103/1673-5374.371368 10.3389/fimmu.2020.01609 10.1128/mbio.02073-23 10.3892/or.2017.5775 10.1038/ncomms11364 10.1371/journal.pone.0044956 10.1158/0008-5472.CAN-22-1270 10.1128/iai.00495-23 10.1016/j.cell.2024.03.011 10.1016/j.lfs.2008.11.020 10.1172/JCI161944 10.1016/j.bbamcr.2020.118665 10.1186/s12885-015-1521-5 10.1128/MCB.25.10.4211-4220.2005 10.1016/j.molimm.2023.12.011 10.1186/s12885-016-3039-x 10.1126/science.1171529 10.1080/13510002.2022.2088011 10.1016/j.neuroscience.2024.02.014 10.1038/s41467-019-12384-2 10.1016/0959-8049(95)00050-X 10.1074/jbc.M111.265082 10.7554/eLife.41517 10.1080/14786419.2023.2298383 10.1016/S2666-5247(22)00359-7 10.4049/jimmunol.180.5.3329 10.1038/s41419-024-06455-6 10.3892/mmr.2024.13195 10.3389/fphar.2022.906043 10.1021/acsami.2c21529 10.1080/10717544.2022.2111480 10.1016/j.abb.2023.109673 10.1371/journal.pone.0041024 10.4049/jimmunol.2300107 10.1126/sciadv.adh2358 10.3389/fimmu.2023.1233630 10.3389/fimmu.2022.946929 10.1016/j.molimm.2022.12.007 10.1021/acsinfecdis.4c00079 10.1111/jcmm.16980 10.1016/j.cell.2016.02.034 10.1016/j.biopha.2020.110755 10.1186/s12951-022-01703-3 10.1038/s41401-021-00773-7 10.4049/jimmunol.2200555 10.1177/1533034615624583 10.1038/s41565-024-01618-0 10.3389/fmicb.2022.829870 10.1016/j.micpath.2023.106021 10.3389/fimmu.2022.1044592 10.1128/mbio.01535-23 10.3390/microorganisms11122998 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. The Author(s) 2024 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: The Author(s) 2024 2024 |
| DBID | AAYXX CITATION NPM ISR 7X8 5PM DOA |
| DOI | 10.1186/s12953-024-00235-y |
| DatabaseName | CrossRef PubMed Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1477-5956 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_c46bf07e53c14948816290fb1c643c29 PMC11619108 A818994371 39633431 10_1186_s12953_024_00235_y |
| Genre | Journal Article |
| GeographicLocations | United States China |
| GeographicLocations_xml | – name: China – name: United States |
| GroupedDBID | --- 0R~ 29P 2WC 53G 5VS 7X7 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IGS IHR ISR ITC KQ8 LK8 M48 M7P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M -A0 3V. ACRMQ ADINQ C24 FRP NPM PMFND 7X8 PQGLB 5PM PUEGO |
| ID | FETCH-LOGICAL-c521t-df39340b16c29e14bb54d2add6c444740cdae06767e0e0659bef1dbf7030511b3 |
| IEDL.DBID | M48 |
| ISSN | 1477-5956 |
| IngestDate | Wed Aug 27 01:19:35 EDT 2025 Thu Aug 21 18:34:58 EDT 2025 Fri Jul 11 16:57:39 EDT 2025 Tue Jun 17 21:56:09 EDT 2025 Tue Jun 10 21:04:58 EDT 2025 Fri Jun 27 05:14:38 EDT 2025 Thu Jan 02 22:28:38 EST 2025 Tue Jul 01 01:18:57 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Proteome Mycobacterium tuberculosis H37Ra Norcantharidin Macrophage |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c521t-df39340b16c29e14bb54d2add6c444740cdae06767e0e0659bef1dbf7030511b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12953-024-00235-y |
| PMID | 39633431 |
| PQID | 3146521482 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c46bf07e53c14948816290fb1c643c29 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11619108 proquest_miscellaneous_3146521482 gale_infotracmisc_A818994371 gale_infotracacademiconefile_A818994371 gale_incontextgauss_ISR_A818994371 pubmed_primary_39633431 crossref_primary_10_1186_s12953_024_00235_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-04 |
| PublicationDateYYYYMMDD | 2024-12-04 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Proteome science |
| PublicationTitleAlternate | Proteome Sci |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | Z Zhang (235_CR19) 2024; 29 D Cruz-Zarate (235_CR58) 2021; 11 DJ Cox (235_CR30) 2020; 11 SA Hwang (235_CR6) 2020; 50 S Vassilopoulos (235_CR46) 2009; 324 I Mwebaza (235_CR26) 2023; 211 Y Ye (235_CR33) 2022; 13 Y Zhang (235_CR42) 2024; 15 YC Chen (235_CR22) 2009; 84 LE Mendonca (235_CR41) 2022; 13 SH Son (235_CR43) 2023; 14 J Pan (235_CR54) 2024; 15 KN Bhengu (235_CR34) 2023; 11 B Olety (235_CR57) 2010; 584 J Zheng (235_CR14) 2023; 38 XP Li (235_CR20) 2015; 15 Z Palcekova (235_CR36) 2024; 10 Q Xu (235_CR51) 2024; 19 PJ Maglione (235_CR29) 2008; 180 PK Gupta (235_CR32) 2023; 14 SO Rahaman (235_CR48) 2011; 286 X Zheng (235_CR53) 2023; 83 XH Liu (235_CR13) 1995; 31A EA Latomanski (235_CR47) 2018; 14 P Babele (235_CR44) 2023; 11 P Qiu (235_CR18) 2017; 17 X Mao (235_CR61) 2023; 9 NR Patel (235_CR59) 2012; 7 M Fumagalli (235_CR45) 2019; 8 S Bagcchi (235_CR1) 2023; 4 A Gupta (235_CR24) 2024; 92 B Ge (235_CR27) 2023; 2023 V Vedham (235_CR49) 2005; 25 A Lovey (235_CR3) 2022; 13 J Zhou (235_CR11) 2020; 131 H Guo (235_CR52) 2024; 544 T Yu (235_CR56) 2019; 10 M Zeng (235_CR63) 2016; 7 H Su (235_CR5) 2016; 6 Q Zhao (235_CR12) 2012; 7 M Zeng (235_CR62) 2020; 1867 S Paik (235_CR4) 2022; 13 J Qiu (235_CR50) 2023; 18 LJ Du (235_CR17) 2022; 43 M Bedard (235_CR28) 2023; 133 H Li (235_CR40) 2023; 744 S Xiao (235_CR10) 2022; 29 S Zhang (235_CR31) 2023; 14 B Li (235_CR23) 2024; 19 X Yu (235_CR38) 2023; 154 J Zheng (235_CR15) 2022; 27 AH Alvarez (235_CR2) 2019; 18 Y Gao (235_CR21) 2017; 38 235_CR8 JY Park (235_CR25) 2024; 166 RD Berg (235_CR60) 2016; 165 L Wang (235_CR7) 2022; 13 W Pu (235_CR39) 2021; 25 YKT de Menezes (235_CR37) 2023; 211 BT Zhai (235_CR9) 2022; 20 Z Han (235_CR16) 2017; 16 T Cao (235_CR55) 2024; 187 235_CR35 |
| References_xml | – volume: 18 start-page: 1219 issue: 12 year: 2019 ident: 235_CR2 publication-title: Expert Rev Vaccines doi: 10.1080/14760584.2019.1704263 – volume: 19 start-page: 230 issue: 1 year: 2024 ident: 235_CR51 publication-title: J Orthop Surg Res doi: 10.1186/s13018-024-04678-z – volume: 6 start-page: 147 year: 2016 ident: 235_CR5 publication-title: Front Cell Infect Microbiol doi: 10.3389/fcimb.2016.00147 – volume: 50 start-page: 429 issue: 4 year: 2020 ident: 235_CR6 publication-title: Ann Clin Lab Sci – volume: 13 start-page: 884 issue: 1 year: 2022 ident: 235_CR3 publication-title: Nat Commun doi: 10.1038/s41467-022-28506-2 – volume: 14 start-page: 1710 issue: 10 year: 2018 ident: 235_CR47 publication-title: Autophagy doi: 10.1080/15548627.2018.1483806 – volume: 14 start-page: e0027223 issue: 4 year: 2023 ident: 235_CR31 publication-title: mBio doi: 10.1128/mbio.00272-23 – volume: 11 start-page: 1846 issue: 7 year: 2023 ident: 235_CR34 publication-title: Microorganisms doi: 10.3390/microorganisms11071846 – volume: 584 start-page: 493 issue: 3 year: 2010 ident: 235_CR57 publication-title: FEBS Lett doi: 10.1016/j.febslet.2009.11.096 – volume: 11 start-page: 7197 issue: 1 year: 2021 ident: 235_CR58 publication-title: Sci Rep doi: 10.1038/s41598-021-85477-y – volume: 18 start-page: 2436 issue: 11 year: 2023 ident: 235_CR50 publication-title: Neural Regen Res doi: 10.4103/1673-5374.371368 – volume: 11 start-page: 1609 year: 2020 ident: 235_CR30 publication-title: Front Immunol doi: 10.3389/fimmu.2020.01609 – volume: 15 start-page: e0207323 issue: 2 year: 2024 ident: 235_CR42 publication-title: mBio doi: 10.1128/mbio.02073-23 – volume: 38 start-page: 1224 issue: 2 year: 2017 ident: 235_CR21 publication-title: Oncol Rep doi: 10.3892/or.2017.5775 – volume: 7 start-page: 11364 year: 2016 ident: 235_CR63 publication-title: Nat Commun doi: 10.1038/ncomms11364 – volume: 7 start-page: e44956 issue: 9 year: 2012 ident: 235_CR12 publication-title: PLoS ONE doi: 10.1371/journal.pone.0044956 – volume: 83 start-page: 2345 issue: 14 year: 2023 ident: 235_CR53 publication-title: Can Res doi: 10.1158/0008-5472.CAN-22-1270 – volume: 92 start-page: e0049523 issue: 4 year: 2024 ident: 235_CR24 publication-title: Infect Immun doi: 10.1128/iai.00495-23 – volume: 187 start-page: 2288 issue: 9 year: 2024 ident: 235_CR55 publication-title: Cell doi: 10.1016/j.cell.2024.03.011 – volume: 84 start-page: 218 issue: 7–8 year: 2009 ident: 235_CR22 publication-title: Life Sci doi: 10.1016/j.lfs.2008.11.020 – volume: 133 start-page: e161944 issue: 6 year: 2023 ident: 235_CR28 publication-title: J Clin Invest doi: 10.1172/JCI161944 – volume: 1867 start-page: 118665 issue: 5 year: 2020 ident: 235_CR62 publication-title: Biochim Biophys Acta Mol Cell Res doi: 10.1016/j.bbamcr.2020.118665 – volume: 15 start-page: 527 year: 2015 ident: 235_CR20 publication-title: BMC Cancer doi: 10.1186/s12885-015-1521-5 – volume: 25 start-page: 4211 issue: 10 year: 2005 ident: 235_CR49 publication-title: Mol Cell Biol doi: 10.1128/MCB.25.10.4211-4220.2005 – volume: 166 start-page: 50 year: 2024 ident: 235_CR25 publication-title: Mol Immunol doi: 10.1016/j.molimm.2023.12.011 – volume: 17 start-page: 55 issue: 1 year: 2017 ident: 235_CR18 publication-title: BMC Cancer doi: 10.1186/s12885-016-3039-x – volume: 324 start-page: 1192 issue: 5931 year: 2009 ident: 235_CR46 publication-title: Science doi: 10.1126/science.1171529 – volume: 27 start-page: 119 issue: 1 year: 2022 ident: 235_CR15 publication-title: Redox Rep doi: 10.1080/13510002.2022.2088011 – volume: 544 start-page: 50 year: 2024 ident: 235_CR52 publication-title: Neuroscience doi: 10.1016/j.neuroscience.2024.02.014 – volume: 10 start-page: 4353 issue: 1 year: 2019 ident: 235_CR56 publication-title: Nat Commun doi: 10.1038/s41467-019-12384-2 – volume: 31A start-page: 953 issue: 6 year: 1995 ident: 235_CR13 publication-title: Eur J Cancer doi: 10.1016/0959-8049(95)00050-X – volume: 286 start-page: 36011 issue: 41 year: 2011 ident: 235_CR48 publication-title: J Biol Chem doi: 10.1074/jbc.M111.265082 – volume: 8 start-page: e41517 year: 2019 ident: 235_CR45 publication-title: eLife doi: 10.7554/eLife.41517 – volume: 38 start-page: 1 issue: 4 year: 2023 ident: 235_CR14 publication-title: Nat Prod Res doi: 10.1080/14786419.2023.2298383 – volume: 4 start-page: e20 issue: 1 year: 2023 ident: 235_CR1 publication-title: Lancet Microb doi: 10.1016/S2666-5247(22)00359-7 – volume: 180 start-page: 3329 issue: 5 year: 2008 ident: 235_CR29 publication-title: J Immunol doi: 10.4049/jimmunol.180.5.3329 – volume: 15 start-page: 66 issue: 1 year: 2024 ident: 235_CR54 publication-title: Cell Death Dis doi: 10.1038/s41419-024-06455-6 – volume: 29 start-page: 71 issue: 5 year: 2024 ident: 235_CR19 publication-title: Mol Med Rep doi: 10.3892/mmr.2024.13195 – volume: 13 start-page: 906043 year: 2022 ident: 235_CR7 publication-title: Front Pharmacol doi: 10.3389/fphar.2022.906043 – ident: 235_CR8 doi: 10.1021/acsami.2c21529 – volume: 29 start-page: 2713 issue: 1 year: 2022 ident: 235_CR10 publication-title: Drug Delivery doi: 10.1080/10717544.2022.2111480 – volume: 744 start-page: 109673 year: 2023 ident: 235_CR40 publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2023.109673 – volume: 7 start-page: e41024 issue: 9 year: 2012 ident: 235_CR59 publication-title: PLoS ONE doi: 10.1371/journal.pone.0041024 – volume: 211 start-page: 1385 issue: 9 year: 2023 ident: 235_CR26 publication-title: J Immunol doi: 10.4049/jimmunol.2300107 – volume: 9 start-page: eadh2358 issue: 36 year: 2023 ident: 235_CR61 publication-title: Sci Adv doi: 10.1126/sciadv.adh2358 – volume: 14 start-page: 1233630 year: 2023 ident: 235_CR32 publication-title: Front Immunol doi: 10.3389/fimmu.2023.1233630 – volume: 13 start-page: 946929 year: 2022 ident: 235_CR4 publication-title: Front Immunol doi: 10.3389/fimmu.2022.946929 – volume: 154 start-page: 24 year: 2023 ident: 235_CR38 publication-title: Mol Immunol doi: 10.1016/j.molimm.2022.12.007 – volume: 10 start-page: 1379 issue: 4 year: 2024 ident: 235_CR36 publication-title: ACS Infect Dis doi: 10.1021/acsinfecdis.4c00079 – volume: 25 start-page: 10504 issue: 22 year: 2021 ident: 235_CR39 publication-title: J Cell Mol Med doi: 10.1111/jcmm.16980 – volume: 165 start-page: 139 issue: 1 year: 2016 ident: 235_CR60 publication-title: Cell doi: 10.1016/j.cell.2016.02.034 – volume: 131 start-page: 110755 year: 2020 ident: 235_CR11 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2020.110755 – volume: 20 start-page: 509 issue: 1 year: 2022 ident: 235_CR9 publication-title: J Nanobiotechnology doi: 10.1186/s12951-022-01703-3 – volume: 43 start-page: 1521 issue: 6 year: 2022 ident: 235_CR17 publication-title: Acta Pharmacol Sin doi: 10.1038/s41401-021-00773-7 – volume: 211 start-page: 601 issue: 4 year: 2023 ident: 235_CR37 publication-title: J Immunol doi: 10.4049/jimmunol.2200555 – volume: 16 start-page: 33 issue: 1 year: 2017 ident: 235_CR16 publication-title: Technol Cancer Res Treat doi: 10.1177/1533034615624583 – volume: 19 start-page: 834 issue: 6 year: 2024 ident: 235_CR23 publication-title: Nat Nanotechnol doi: 10.1038/s41565-024-01618-0 – volume: 2023 start-page: 1 issue: 31 year: 2023 ident: 235_CR27 publication-title: Cell Host Microbe – volume: 13 start-page: 829870 year: 2022 ident: 235_CR33 publication-title: Front Microbiol doi: 10.3389/fmicb.2022.829870 – ident: 235_CR35 doi: 10.1016/j.micpath.2023.106021 – volume: 13 start-page: 1044592 year: 2022 ident: 235_CR41 publication-title: Front Immunol doi: 10.3389/fimmu.2022.1044592 – volume: 14 start-page: e0153523 issue: 5 year: 2023 ident: 235_CR43 publication-title: mBio doi: 10.1128/mbio.01535-23 – volume: 11 start-page: 2998 issue: 12 year: 2023 ident: 235_CR44 publication-title: Microorganisms doi: 10.3390/microorganisms11122998 |
| SSID | ssj0022926 |
| Score | 2.3544905 |
| Snippet | Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the regulation... Abstract Tuberculosis drug resistance contributes to the spread of tuberculosis. Immunotherapy is an effective strategy for treating tuberculosis, with the... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 13 |
| SubjectTerms | BCG BCG vaccines Chromatin Drug resistance in microorganisms Enzymes G proteins H37Ra Immunotherapy Liquid chromatography Macrophage Macrophages Mycobacterium tuberculosis Norcantharidin Patient compliance Proteome T cells Tuberculosis |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hnrggaHkYCloQggNadV_Z2Me0oiqI9EBTqbfVvkw41IY6OeTW_8A_5Jcws3aqWBy4cPVOpOzM7Hwz9sy3hLw1TtUpSsViiFCgpKgYJEeRJWegGItR8jwkNj83Z5f689XkaueqL-wJ6-mBe8UdBW18zadpooJAKpNSGFnx2osAWBpkHt0DzNsWU0OpJStptiMypTnqANUm-L1Ss0zwwjYjGMps_X_H5B1QGjdM7iDQ6UPyYEgd6az_y4_IvdTsk4NZA2Xz9Ya-o7mZM78lPyDxy8nv21_zC4YoFenPtWtWAxs3bWua2RlwHpn2g78dhdIcjByp39Dz9gb1vYQqGoANVuh8ccwWmF2CwLXDS7-WEIa6x-Ty9OPi5IwNFyqwgPcWsFirSmnuhQHFJaG9n-goIcKZoLWeah6iSxwp3BJP-MHVp1pEX-eoIIRXT8he0zbpGaEll0lL7iYcfipTWfEUIdV01VQ5H-qyIB-2-rU_et4Mm-uN0tjeGhasYbM17KYgx2iCO0nkvM4PwBPs4An2X55QkDdoQIusFg22zXxz666zny6-2hmkJVWl1VQU5P0gVLdgyuCGKQTYFRJhjSQPR5Jw7MJo-fXWTywuYa9ak9p1ZxWAD6hbl7IgT3u_uduYgninIGcrSDnyqNHOxyvN92Vm_RaQm0NuVz7_H7p6Qe5LPA3Yl6MPyd7qZp1eQna18q_yQfoDRtQhmQ priority: 102 providerName: Directory of Open Access Journals |
| Title | LC–MS-based quantitation of proteomic changes induced by Norcantharidin in MTB-Treated macrophages |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39633431 https://www.proquest.com/docview/3146521482 https://pubmed.ncbi.nlm.nih.gov/PMC11619108 https://doaj.org/article/c46bf07e53c14948816290fb1c643c29 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LbxMxELb6uHBBlPJYKJFBCA7I4LW9rwNCSdWqIBKhNJEiLtb6sU0luttmE4nc-A_8Q34JY-8m6opeuOwhnqxkz3s98w1Cr-OcF9YwTow2kKBYwwkER4bYPIZkzBhGfZPYcBSfTcWXWTTbQZtxR-0B1nemdm6e1HTx4_3Pm_UnUPiPXuHT-EMNPityt5GCePgWst5F--CZEqeoQ7G9VWAsY023UZKQCBKDTRPNne_oOCqP5_-v1b7ltrollbd81OkDdL8NLnG_kYYDtGPLh-iwX0JifbXGb7Av9_Tf0Q-R-Xr859fv4Tlxfszgm1VeLlu8blwV2OM3uI5l3LQG1xiSdxADg9Uaj6qF48gc8mxwfbCCh5MBmbj4EwiucjcWbA6Gqn6Epqcnk-Mz0o5cINpNNiCm4BkXVIWxZpkNhVKRMAxsYKyFEImg2uSWOpA3S627klW2CI0qvN0IQ8Ufo72yKu1ThFPKrGA0jyj8ldk0o9ZAMJpnCc-VLtIAvducr7xukDWkz0jSWDbckMAN6bkh1wEaOBZsKR0qtv-hWlzIVsmkFrEqaGIjrkMHe5OGMctooUINcRdsKECvHAOlw70oXWHNRb6qa_n5fCz7ELhkmeBJGKC3LVFRASt13vYpwK4cVFaH8qhDCYqpO8svN3Ii3ZKrZitttaolB_cExy1SFqAnjdxsN8bBInKI6gKUdiSqs_PuSnk597jgIUTvEP2lz_7rZJ-je8yJvSvREUdob7lY2RcQaC1VD-0ms6SH9gcno2_jnv9c0fMaBc_x4Ptf73sn-Q |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LC%E2%80%93MS-based+quantitation+of+proteomic+changes+induced+by+Norcantharidin+in+MTB-Treated+macrophages&rft.jtitle=Proteome+science&rft.au=Wu%2C+Yi-Lin&rft.au=Li%2C+Yuan-Ting&rft.au=Liu%2C+Gan-Bin&rft.au=Wu%2C+Jin-Lin&rft.date=2024-12-04&rft.issn=1477-5956&rft.eissn=1477-5956&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12953-024-00235-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12953_024_00235_y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-5956&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-5956&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-5956&client=summon |